OncologyTube
OncologyTube produces, finds and distributes breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma and many other types of cancer videos for education and information for oncologists, cancer researchers, and patients.
ESMO 2025 Top 10 Breast Cancer Abstracts from Paolo Tarantino, MD
TCR-T Therapy Unveiled: 49% Death Risk Drop & 39% Response in Melanoma & Sarcoma | Oncologist Guide
ESMO 2025 Top 10 Genitourinary Cancer Must-See Abstracts for Oncologists
ICI Myocarditis: 1% Risk, 50% Fatal – UCSF Expert Insights!
TIL Therapy Revolution: 96% Survival & 67% Response in Melanoma - Dr. Allison Betof Warner
ESMO 2025 Top 10 Must See Breast Cancer Abstracts
The Future of Cancer Treatment: 63% pCR Rate with Nivolumab Relatlimab
2025 Breast Cancer Immunotherapy Trials: Key Updates from Dr. LeVee | MOASC/ANCO
FDA Approves Lurbinectedin + Atezolizumab for ES-SCLC: IMforte Trial Breakdown
ASCO 2025: Dr. Hafez’s 25% pCR Lung Cancer Immunotherapy Breakthrough
FDA Approves Inluriyo (Imlunestrant) for ESR1-Mutated Breast Cancer - EMBER-3 Insights
Uncommon EGFR Mutations Lung Cancer: MOASC 2025
Alcohol and Cancer Risk: 2025 Surgeon General’s Warning Uncovered | OncologyTube Exclusive
Melanoma & Skin Cancer Updates 2025 ASCO: Immunotherapy First? | Dr. Gino K. In at MOASC Spotlight
Bilateral Breast Cancer Case Study: Anti-Yo PCD Revealed by Dr. Nirja Shah, MD | MOASC 2025
Head and Neck Cancer: ASCO 2025 Treatment Insights with Dr. Victoria Villaflor
Gastric Cancer Immunotherapy: Dr. Iqbal’s MATTERHORN Insights
Breast Cancer Breakthroughs: ASCO 2025 Updates with Dr. Lavasani
What are the latest updates on Tarlatamab, NeoADAURA, key lung cancer treatments from ASCO 2025?
What are the key insights from ASCO 2025 on ovarian cancer?
FDA Approves INLEXZO™ / Gemcitabine Intravesical Bladder Cancer Breakthrough (2025)
31% Lower Colon Cancer Recurrence with Exercise: Must-Know ASCO & MOASC 2025 Updates for Oncologists
Immuno-Oncology Symposium 2025 Omid Hamid, MD MOASC / ANCO
55% OS Boost in Urothelial Cancer with Enfortumab Vedotin + Pembrolizumab: Must-See ASCO Insights
NSCLC HER3-DXd: Breakthrough in Resistant Cases – HERTHENA-Lung02 Study
The AMPLIFY-201 Trial: A Breakthrough in Pancreatic Cancer?
Breast Cancer ALND cN2/N3: Benefits, Risks & Alternatives Explained | Dr. Roshni Rao
Male Breast Cancer Treatment: New Insights from ASBrS 2025
Breast Cancer Treatment: How CDK4/6 Inhibitors Work (monarchE & NATALEE Trials)
Mastectomy Sensation-Preserving Dr. Anne Peled ASBrS Insights